All In Biotech

Investigational drug · Phase 2

NDI-101150

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "NDI-101150"

First trial start

2021

Nov 5, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "NDI-101150", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Solid Tumor
  • Renal Cell Carcinoma (Kidney Cancer)
  • Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Non-Small Cell Lung Cancer

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Kidney cancer (renal cell carcinoma) · Stomach and esophageal cancer · Oncology · Kidney and urology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "NDI-101150" as an intervention, largest first.

All trials
  • Nimbus Saturn, Inc.Industry

    NCT05128487 · 106 participants (planned) · Start Nov 5, 2021 · Primary completion Feb 2025

    Drug: NDI-101150; Pembrolizumab · For: Solid Tumor; Renal Cell Carcinoma (Kidney Cancer); Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and 1 more

    Sites: Scottsdale, Arizona; New Haven, Connecticut; Washington D.C., District of Columbia · 19 sites in all

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Solid Tumor

  • BMS-986507BL-B01D1, Iza-brenPhase 351 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma

  • SintilimabIBI308Phase 321 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma

  • IfebemtinibIN10018, BI853520Phase 311 trials

    InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer

  • JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials

    Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor

  • FavezelimabMK-4280, MK-4820APhase 39 trials

    Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors

  • Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma

  • PD-1 inhibitorPhase 38 trials

    BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)

  • RC148Phase 38 trials

    RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.